No Data
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
China Resources Pharmaceutical Group's (HKG:3320) Investors Will Be Pleased With Their Decent 43% Return Over the Last Three Years
CHINARES PHARMA: China Resources Sanjiu Medical & Pharmaceutical's net income attributable to shareholders for the year 2024 is 3.369 billion yuan, an increase of 18.1% year-on-year.
CHINARES PHARMA (03320) announced that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), achieved a total operating income of 27.617 billion yuan for the year ending December 31, 2024, an increase of 11.63% year-on-year; the Net income attributable to the shareholders of the listed company was 3.369 billion yuan, an increase of 18.1% year-on-year; basic earnings per share were 2.63 yuan.
China Resources Pharmaceutical's Shenzhen Listed Subsidiary Records 18% Higher Net Attributable Profit for 2024
CHINARES PHARMA: ANNOUNCEMENTPRELIMINARY FINANCIAL INFORMATION OF CR SANJIUFOR THE YEAR ENDED 31 DECEMBER 2024
